Clinical Trial Detail

NCT ID NCT02348008
Title Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Arkadiusz Z. Dudek, MD
Indications

clear cell renal cell carcinoma

Therapies

Bevacizumab + Pembrolizumab

Age Groups: adult

No variant requirements are available.